Biotechnology company ProBio has launched its Plasmid & Viral Vector Center of Excellence in Hopewell. The company, a subsidiary of GenScript Biotech Corporation, is a global contract development and manufacturing organization that specializes in cell and gene therapy.
In addition to its new Hopewell facility, a custom-built 128,000-square-foot space on the Princeton West Innovation Campus, the company also has locations in China, Hong Kong, the Netherlands, Japan, and Korea.
The Hopewell site is equipped to support clinical-stage development, process-development, and scale-up for cell and gene therapy programs. “This is not just a new facility. It is a beacon of hope for patients waiting for cures,” said Allen Guo, CEO of ProBio, in a press release. “Opening the Hopewell center is a milestone in ProBio’s global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.”
At a ribbon cutting and open house event celebrating the facility’s opening, John Coelho of NJEDA emphasized the strategic significance of the opening: “The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.”
ProBio, 311 Pennington Rocky Hill Road, Building 9, Pennington 08534; 732-885-9188. Allen Guo, CEO. www.probiocdmo.com.
